购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
顶部生物活性化学信息储存和溶解信息计算器

VEL-0230

Rating icon 还可以
产品编号 T69793Cas号 221144-20-3

VEL-0230, also known as NC-2300, is a potent cathespin K inhibitor. VEL-0230 has dual-acting properties that both stimulates bone formation and inhibits loss. VEL-0230 is being studied preclinically for the treatment of diseases involving bone mineral disorders such as bone loss related to multiple myeloma, osteoporosis, bone metastases, and rheumatoid arthritis. Velcura Therapeutics is currently being developed by Velcura Therapeutics. Given VEL- 0230's promotion of bone formation, inhibition of bone loss and reduction of calcium levels, Velcura has chosen Myeloma as its lead indication, as the bone fragility, bone pain, high calcium levels and eventual kidney involvement present serious medical and quality of life issues to affected patients.

VEL-0230

VEL-0230

Rating icon 还可以
产品编号 T69793Cas号 221144-20-3

VEL-0230, also known as NC-2300, is a potent cathespin K inhibitor. VEL-0230 has dual-acting properties that both stimulates bone formation and inhibits loss. VEL-0230 is being studied preclinically for the treatment of diseases involving bone mineral disorders such as bone loss related to multiple myeloma, osteoporosis, bone metastases, and rheumatoid arthritis. Velcura Therapeutics is currently being developed by Velcura Therapeutics. Given VEL- 0230's promotion of bone formation, inhibition of bone loss and reduction of calcium levels, Velcura has chosen Myeloma as its lead indication, as the bone fragility, bone pain, high calcium levels and eventual kidney involvement present serious medical and quality of life issues to affected patients.

规格价格库存数量
25 mg¥ 10,6006-8周
50 mg¥ 13,8006-8周
100 mg¥ 17,5006-8周
大包装 & 定制
加入购物车
实验操作小课堂
查看更多
联系我们获取更多批次信息
资源下载
产品操作手册
TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
VEL-0230, also known as NC-2300, is a potent cathespin K inhibitor. VEL-0230 has dual-acting properties that both stimulates bone formation and inhibits loss. VEL-0230 is being studied preclinically for the treatment of diseases involving bone mineral disorders such as bone loss related to multiple myeloma, osteoporosis, bone metastases, and rheumatoid arthritis. Velcura Therapeutics is currently being developed by Velcura Therapeutics. Given VEL- 0230's promotion of bone formation, inhibition of bone loss and reduction of calcium levels, Velcura has chosen Myeloma as its lead indication, as the bone fragility, bone pain, high calcium levels and eventual kidney involvement present serious medical and quality of life issues to affected patients.
化学信息
分子量309.33
分子式C14H24NNaO5
CAS No.221144-20-3
储存&溶解度
存储Shipping with blue ice.

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ，每只动物体重 20 g ，给药体积 100 μL ， TargetMol | Animal experiments 一共给药动物 10 只 ，您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL 。
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent （ 母液浓度为 40 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法: 取 50μLDMSOTargetMol | reagent 母液，添加 300 μLPEG300TargetMol | reagent 混匀澄清，再加 50μLTween 80, 混匀澄清，再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例，并不是具体某个化合物的推荐配制方式，请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算，您也可以参考 更多

关键词

HMN1180VEL-0230VEL0230HMN-1180VEL 0230

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

233
Related Tags: buy VEL-0230 | purchase VEL-0230 | VEL-0230 cost | order VEL-0230 | VEL-0230 chemical structure | VEL-0230 formula | VEL-0230 molecular weight
TargetMol | Logo

版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.

沪ICP备20019793号-4沪公网安备 31010602006700号TargetMol | Copyright